Ad
related to: ivig patient information leaflet fda list
Search results
Results from the WOW.Com Content Network
An initial post-marketing study was updated in 2021 to verify the clinical benefits of VIGIV (CNJ-016, Vaccinia Immune Globulin Intravenous (Human), sterile solution) in the resolution of complications resulting from Orthopoxvirus vaccination in eligible patients treated with VIGIV named Clinical Outcomes of VIGIV Treatment of Smallpox ...
The first patient package insert required by the FDA was in 1968, mandating that isoproterenol inhalation medication must contain a short warning that excessive use could cause breathing difficulties. [4] [non-primary source needed] The second patient package insert required by the FDA was in 1970, mandating that combined oral contraceptive ...
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Rho(D) immune globulin is made up of antibodies to the antigen Rh o (D) present on some red blood cells. [2] It is believed to work by blocking a person's immune system from recognizing this antigen. [2] Rh o (D) immune globulin came into medical use in the 1960s, [4] following the pioneering work of John G. Gorman.
The first report of immunizing an animal of one species (guinea pig) against the immune cells of another species (mouse lymphocytes) was by Élie Metchnikoff in 1899. He reported injecting cells recovered from mouse lymph nodes into Guinea pigs and waiting for the immunization to result in the accumulation of anti-mouse antibodies in the Guinea pig blood.
Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. [1] It is used to prevent tetanus in those who have a wound that is at high risk, have not been fully vaccinated with tetanus toxoid , or have HIV/AIDS .
Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. [10] It is used to prevent rabies following exposure. [10] It is given after the wound is cleaned with soap and water or povidone-iodine and is followed by a course of rabies vaccine. [10]
HBIG should be given within 14 days of exposure to the hepatitis B virus. [7] The half-life of HBIG is about 3 weeks. In lieu of a booster administration of HBIG, a hepatitis B vaccination is initiated at the time of the initial HBIG administration, thus providing long term protection.
Ad
related to: ivig patient information leaflet fda list